Eton licenses Aquestive's Libervant seizure rescue film for exclusive US commercialisation
Eton Pharmaceuticals has secured exclusive US commercialisation rights to Aquestive Therapeutics' Libervant diazepam buccal film for the investigational treatment of seizure clusters.
The licensing and supply agreement gives Eton responsibility for US commercialisation while Aquestive remains the exclusive manufacturer and supplier of the diazepam buccal film formulation.
Aquestive is eligible for mid-teens royalties on annual net sales, with a potential April 2027 commercial launch dependent on final FDA approval.
Field | Content |
Article Type | Deals |
Companies | Eton Pharmaceuticals; Aquestive Therapeutics |
Deal Type | Exclusive US licensing and supply agreement |
Licensed Product | Libervant |
Active Ingredient | Diazepam |
Dosage Form | Buccal film |
Therapeutic Area | Neurology; seizure clusters |
Product Status | Investigational for the intended US commercial launch; final FDA approval pending |
Licensing Rights | Exclusive US commercialisation rights granted to Eton |
Manufacturing and Supply | Aquestive remains the exclusive manufacturer and supplier |
Royalties | Mid-teens percentage of annual net sales |
Upfront Payment | Not disclosed in supplied summary |
Expected Commercial Launch | April 2027 subject to final FDA approval |
Geography | United States |
What Happened | Eton and Aquestive signed an exclusive US licensing and supply agreement for Libervant diazepam buccal film. |
Why It Matters | The agreement establishes a dedicated commercial partner for a potential seizure-cluster rescue treatment while preserving Aquestive's manufacturing role. |
Strategic Rationale | Eton gains a potential specialty neurology product while Aquestive retains supply responsibilities and participates in future sales through royalties. |
Key Takeaway | Eton holds exclusive US commercialisation rights to Libervant but the product's anticipated launch depends on final FDA approval. |
What to Watch | FDA regulatory decision, launch preparations, product availability, reimbursement and subsequent sales performance. |
Primary Source | Eton Pharmaceuticals and Aquestive Therapeutics announcement |
Relevant Date | 14 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentarios